Dupixent

Active Ingredient(s): Dupilumab
FDA Approved: * March 28, 2017
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Skin Care

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.[3][4][5][1] Side effects include decreased levels of T helper cells, cold sores, allergic reactions and inflammation of the cornea.[4] It was developed by Regeneron Pharmaceuticals... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Dupixent 100 mg/.67ml Subcutaneous Injection, Solution

NDC: 0024-5911

Labeler:

Sanofi-aventis U.S. LLC

Dupixent 300 mg/2ml Subcutaneous Injection, Solution

NDC: 0024-5914

Labeler:

Sanofi-aventis U.S. LLC

Dupixent 300 mg/2ml Subcutaneous Injection, Solution

NDC: 0024-5915

Labeler:

Sanofi-aventis U.S. LLC

Dupixent 300 mg/2ml Subcutaneous Injection, Solution

NDC: 0024-5916

Labeler:

Sanofi-aventis U.S. LLC

Dupixent 200 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5918

Labeler:

Sanofi-aventis U.S. LLC

Dupixent 200 mg/1.14ml Subcutaneous Injection, Solution

NDC: 0024-5919

Labeler:

Sanofi-aventis U.S. LLC